title: Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction.
abstract: BACKGROUND
  The optimal percutaneous interventional strategy for dealing with significant non-culprit lesions in patients with multivessel disease (MVD) with acute myocardial infarction (AMI) at presentation remains controversial.
  
  
  METHODS
  A total of 820 patients treated with primary angioplasty for AMI between 1998 and 2002 were classified in groups of patients with single vessel disease (SVD) or MVD (> or =70% stenosis of > or =2 coronary arteries). Patients with MVD were subdivided in 3 groups on the basis of the revascularization strategy: 1) patients undergoing percutaneous coronary intervention (PCI) of the infarct-related artery (IRA) only; 2) patients undergoing PCI of both the IRA and non-IRA(s) during the initial procedure; and 3) patients undergoing PCI of the IRA followed by staged, in-hospital PCI of the non-IRA(s). Procedural, 30-day, and 1-year outcomes are reported.
  
  
  RESULTS
  At 1 year, compared with patients with SVD, patients with MVD had a higher incidence of re-infarction (5.9% vs 1.6%, P =.003), revascularization (18% vs 9.6%, P <.001), mortality (12% vs 3.2%, P <.001), and major adverse cardiac events (MACEs; 31% vs 13%, P <.001). In patients with MVD, compared with PCI restricted to the IRA only, multivessel PCI was associated with higher rates of re-infarction (13.0% vs 2.8%, P <.001), revascularization (25% vs 15%, P =.007), and MACEs (40% vs 28%, P =.006). Multivessel PCI was an independent predictor of MACEs at 1 year (odds ratio = 1.67, P =.01).
  
  
  CONCLUSIONS
  These data suggest that in patients with MVD, PCI should be directed at the IRA only, with decisions about PCI of non-culprit lesions guided by objective evidence of residual ischemia at late follow-up. Further studies are needed to confirm these findings.
authors.affiliation: Section of Cardiology, Biostatistics, and Outcomes Research, Mid America Heart Institute, St. Luke's Hospital, Kansas City, Mo 64111, USA.
authors.forename: Roberto A
authors.initials: RA
authors.lastname: Corpus
authors.forename: John A
authors.initials: JA
authors.lastname: House
authors.forename: Steven P
authors.initials: SP
authors.lastname: Marso
authors.forename: J Aaron
authors.initials: JA
authors.lastname: Grantham
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Huber
authors.forename: Steven B
authors.initials: SB
authors.lastname: Laster
authors.forename: Warren L
authors.initials: WL
authors.lastname: Johnson
authors.forename: William C
authors.initials: WC
authors.lastname: Daniels
authors.forename: Charles W
authors.initials: CW
authors.lastname: Barth
authors.forename: Lee V
authors.initials: LV
authors.lastname: Giorgi
authors.forename: Barry D
authors.initials: BD
authors.lastname: Rutherford
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000150:complications / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D016896:Treatment Outcome